Pfenex Inc. and Arcellx, Inc. announced a Development, Evaluation and License agreement under which Arcellx gains access to the proprietary Pfenex Expression Technology® platform to advance multiple proprietary sparX proteins that activate, silence and reprogram Antigen- Receptor Complex T cell-based therapies. Technology transfer of the program to a cGMP manufacturing facility is underway. The success of the first program has encouraged both parties to initiate a second sparX program; both prog...